Ulcerative Colitis Market and Forecast Analysis

Boston, MA

ReportsWorldwide has announced the addition of a new report title Ulcerative Colitis Market and Forecast Analysis to its growing collection of premium market research reports.

Ulcerative colitis is a chronic inflammatory bowel disease that is characterized by inappropriate diffuse inflammation of the rectal and colonic mucosa, which occurs in the innermost layer of the intestinal lining. Ulcerative colitis is a chronic, incurable disease with low mortality that is generally diagnosed in adolescence and early adulthood.

Ulcerative colitis is currently an idiopathic condition, the pathogenesis of which is yet to be fully elucidated. However, it is known to involve an interaction between genetics, the immune system, and environmental factors. Risk factors include ethnicity, family history, antibiotic or non-steroidal anti-inflammatory agent use, and diet. Incidence and prevalence have been increasing over the past two decades in most regions of the world.

Datamonitor Healthcare estimates that in 2015, there were 2.1 million diagnosed prevalent cases of ulcerative colitis in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK). Over 2015–35, the number of prevalent cases is expected to increase to 2.5 million (16.6% increase).

For a Detailed description and table of contents of this report please click here: https://www.reportsworldwide.com/report/ulcerative-colitis-market-and-forecast-analysis

Below are the key topics covered in this Report :

• TREATMENT: ULCERATIVE COLITIS

Executive Summary
Primary Research Methodology
Patient Segmentation
Country Treatment Trees: Crohn’s Disease
Country Treatment Trees: Ulcerative Colitis
Current Treatment Options
Prescribing Trends: Crohn’s Disease
Prescribing Trends: Ulcerative Colitis
Prescribing Influences
Unmet Needs in Inflammatory Bowel Disease

• EPIDEMIOLOGY: ULCERATIVE COLITIS

Executive Summary
Disease Background
Sources and Methodology
Forecast
Epidemiologist Insight
Strengths and Limitations
Appendix

• MARKETED DRUGS: ULCERATIVE COLITIS

Executive Summary
Product Overview
Product profile: Apriso
Product profile: Delzicol/Asacol HD
Product profile: Entyvio
Product profile: Humira
Product profile: Lialda
Product profile: Pentasa
Product profile: Remicade
Product profile: Simponi
Product profile: Uceris

• PIPELINE: ULCERATIVE COLITIS

Executive Summary
Clinical Pipeline Overview
Target Product Profile
Product profile (late stage): LT-02
Product profile (late stage): Xeljanz
Product profile (late stage): etrolizumab

• APPENDIX

Appendix: Marketed Drugs: Ulcerative Colitis
Appendix: Pipeline: Ulcerative Colitis

To Get Sample Copy of Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=35943

About ReportsWorldwide.com

ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-1947
abigail@reportsworldwide.com

This release was published on openPR.